Different levels of replicates and how to create a correct targets file out of that.
1
0
Entering edit mode
Naomi Altman ★ 6.0k
@naomi-altman-380
Last seen 4.0 years ago
United States
Material relevant to this discussion can be found under the thread with subject line: technical replicates (again!): a summary At 02:21 AM 3/31/2004, Johan Lindberg wrote: >Thank you for the answer but I think that my situation is a little bit >different. First of all I wonder about the answer that was given >in https://stat.ethz.ch/pipermail/bioconductor/2003-December/003277.html >He has got 30 individuals with 4-6 replicates of each. This would mean >that 120 - 160 hybridizations have been done. The example targets file >that is given looks something like this: > >Cy3 Cy5 >Patient1 Control >Control Patient1 >Patient1 Control >Patient2 Control >Control Patient2 >... > >Here is were I get confused because it looks here as the technical >replicates are included in the targets file (on the same level as the >biological replicates) and should therefore also be included in a >following contrast matrix. But the contrast.matrix given >cont.matrix <- matrix(1,30,1) >is just a row of 30 1:s (he had 30patients in the study) witch indicates >that only the true biological replicates would be included in the B-stat >analysis??? >Back to my experiment. My real problem I think is that I have no common >reference between the different samples. In the example above he has got >this "control" used in the hybridizations. But I have hybridized a biopsy >before and then after treatment for each individual. > >Cy3 Cy5 >Patient1 before Patient1 after >Patient1 after Patient1 before >Patient2 before Patient2 after >... > >But since the effect I am looking for is the effect of the treatment, not >the between patients effect, would it be correct to use the same approach >as the given example >https://stat.ethz.ch/pipermail/bioconductor/2003-December/003277.html >even though I have no common reference? > >Another question that was not aswered is how to treat different replicates >on different levels. Since I have 1-2 biopsy taken from different >individuals plus technical replicates of each. Is there a way of dealing >with this kind of stuff in LIMMA? Should one just average over lower >levels of replicates and then just put in true biological replicates in >the targets file/contrast matrix? > >Best regards > >/ Johan Lindberg > > > > > > > > >At 10:32 2004-03-31 +1000, Gordon Smyth wrote: >>At 11:51 PM 30/03/2004, Johan Lindberg wrote: >>>Sorry, I forgot to have a subject on the mail I sent before. >>> >>>Hello everyone. >>>I would really appreciate some comments/hints/help with a pretty long >>>question. >> >>This question has been asked on the list before. See: >> >>https://stat.ethz.ch/pipermail/bioconductor/2003-December/003277.htm l >> >>The simplest treatment in limma is simply to treat your experiment as >>having two factors, one factor having 10 levels indicating the patient >>and one taking two levels, before or after. This treatment is analogous >>to a paired-test or to a two-way analysis of variance. >> >>An alternative treatment would be to treat the patients as random >>effects. That would also be a correct treatment, and potentially a little >>more powerful, but also much more difficult and I don't think you gain >>very much. >> >>>I have an experiment consisting of 18 hybridizations. On the 30K cDNA >>>arrays knee joint bioipsies (from different patients) before and after a >>>certain treatment is hybridized. What I want to find out is the effect >>>of the treatment, not the difference between the patients. The problem >>>is how to deal with different levels of replicates and how to create a >>>correct target file since I have no common reference? >>>This is how the experimental set-up looks like. >>> >>>Patient Hybridization Cy3 Cy5 >>>1 1A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 1B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>>3 2A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 2B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>> 3A Biopsy 2 before >>> treatment Biopsy 2 after treatment >>> 3B Biopsy 2 after >>> treatment Biopsy 2 before treatment >>>4 4A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 4B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>> 5A Biopsy 2 before >>> treatment Biopsy 2 after treatment >>> 5B Biopsy 2 after >>> treatment Biopsy 2 before treatment >>>5 6A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 6B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>>6 7A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 7B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>>7 8A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 8B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>>10 9A Biopsy 1 before >>>treatment Biopsy 1 after treatment >>> 9B Biopsy 1 after >>> treatment Biopsy 1 before treatment >>> >>>As you can see different patients have one or two biopsies taken from >>>them. Since I realize it would be a mistake to include all those into >>>the target file because if I have more measurements of a certain patient >>>that would bias the ranking of the B-stat towards the patient having the >>>most biopsies in the end, right? Or? >>>Since the differentially expressed genes in the patient with more >>>biopsies will get smaller variance? >>> >>>My solution to the problem was just to create an artificial Mmatrix >>>twice as long as the original MA object. For the patients with two >>>biopsies I averaged over the technical replicates (dye-swaps) and put >>>the values from biopsy one and then the values from biopsy two in the >>>matrix. From patients with just a technical replicate I put the values >>>from hybridization 1A and then hybridization 1B into the matrix. >>> >>>The M-values of that matrix object would look something like: >>> >>> patient >>> 1 patient3 .... >>>Rows 1-30000 Hybridization 1A Average of hybridization 2A and >>>2B .... >>>Rows 30001-60000 Hybridization 1B Average of hybridization >>>3A and 3B .... >>> >>>After this I plan to use dupcor on the new matrix of M-values, as if I >>>would have a slide with replicate spots on it. >>> >>>So far so good or? Is this a good way of treating replicates on >>>different levels or has anyone else some better idea of how to do this. >>>Comments please..... >>> >>> >>>And now, how to create a correct targets file since I have no common >>>reference. >>>I guess it would look something like this: >>> >>>SlideNumber Name FileName Cy3 Cy5 >>>1 pat1_p test1.gpr Before_p1 After_p1 >>>2 pat3_p test2.gpr Before_p2 After_p2 >>>3 pat4_p test3.gpr Before_p3 After_p3 >>>4 pat6_p test4.gpr Before_p4 After_p4 >>>5 pat7_p test5.gpr Before_p5 After_p5 >>>6 pat10_p test6.gpr Before_p6 After_p6 >>> >>>But when I want to make my contrast matrix I am lost since I do not have >>>anything to write as ref. >>>design <- modelMatrix(targets, ref="????????") >>> >>>If I redo the matrix to >>> >>>SlideNumber Name FileName Cy3 Cy5 >>>1 pat1_p test1.gpr Before_p After_p >>>2 pat3_p test2.gpr Before_p After_p >>>3 pat4_p test3.gpr Before_p After_p >>>4 pat6_p test4.gpr Before_p After_p >>>5 pat7_p test5.gpr Before_p After_p >>>6 pat10_p test6.gpr Before_p After_p >>> >>>wouldnt that be the same as treating this as a common reference design >>>when it is not? And wouldnt that effect the variance of the experiment? >>>How do I do this in a correct way. >>>I looked at the Zebra fish example in the LIMMA user guide but isnt that >>>wrong as well. Because technical and biological replicates are treated >>>the same way in the targets file of the zebra fish. >> >>Dye-swap pairs are not necessarily technical replicates. >> >>>I realize that many of these questions should have been considered >>>before conducting the lab part but unfortunately they were not. So I >>>will not be surprised if someone sends me the same quote as I got >>>yesterday from a friend: >>> >>>"To consult a statistician after an experiment is finished is often >>>merely to ask him to conduct a post mortem examination. He can perhaps >>>say what the experiment died of." >>>- R.A. Fisher, Presidential Address to the First Indian Statistical >>>Congress, 1938 >>> >>>Best regards >> >>Gordon >> >>>/Johan Lindberg >>> >>>_______________________________________________ >>>Bioconductor mailing list >>>Bioconductor@stat.math.ethz.ch >>>https://www.stat.math.ethz.ch/mailman/listinfo/bioconductor > >_______________________________________________ >Bioconductor mailing list >Bioconductor@stat.math.ethz.ch >https://www.stat.math.ethz.ch/mailman/listinfo/bioconductor Naomi S. Altman 814-865-3791 (voice) Associate Professor Bioinformatics Consulting Center Dept. of Statistics 814-863-7114 (fax) Penn State University 814-865-1348 (Statistics) University Park, PA 16802-2111
limma limma • 974 views
ADD COMMENT
0
Entering edit mode
@gordon-smyth
Last seen 15 hours ago
WEHI, Melbourne, Australia
Dear Johan, Now I've had a chance to read your email more thoroughly, I think you actually have a clever approach. At 11:51 PM 30/03/2004, Johan Lindberg wrote: >Sorry, I forgot to have a subject on the mail I sent before. > >Hello everyone. >I would really appreciate some comments/hints/help with a pretty long >question. > >I have an experiment consisting of 18 hybridizations. On the 30K cDNA >arrays knee joint bioipsies (from different patients) before and after a >certain treatment is hybridized. What I want to find out is the effect of >the treatment, not the difference between the patients. The problem is how >to deal with different levels of replicates and how to create a correct >target file since I have no common reference? >This is how the experimental set-up looks like. > >Patient Hybridization Cy3 Cy5 >1 1A Biopsy 1 before >treatment Biopsy 1 after treatment > 1B Biopsy 1 after > treatment Biopsy 1 before treatment >3 2A Biopsy 1 before >treatment Biopsy 1 after treatment > 2B Biopsy 1 after > treatment Biopsy 1 before treatment > 3A Biopsy 2 before > treatment Biopsy 2 after treatment > 3B Biopsy 2 after > treatment Biopsy 2 before treatment >4 4A Biopsy 1 before >treatment Biopsy 1 after treatment > 4B Biopsy 1 after > treatment Biopsy 1 before treatment > 5A Biopsy 2 before > treatment Biopsy 2 after treatment > 5B Biopsy 2 after > treatment Biopsy 2 before treatment >5 6A Biopsy 1 before >treatment Biopsy 1 after treatment > 6B Biopsy 1 after > treatment Biopsy 1 before treatment >6 7A Biopsy 1 before >treatment Biopsy 1 after treatment > 7B Biopsy 1 after > treatment Biopsy 1 before treatment >7 8A Biopsy 1 before >treatment Biopsy 1 after treatment > 8B Biopsy 1 after > treatment Biopsy 1 before treatment >10 9A Biopsy 1 before >treatment Biopsy 1 after treatment > 9B Biopsy 1 after > treatment Biopsy 1 before treatment You have an unbalanced design with three error strata: patient, biopsy, microarray. In principle one would like to treat this using a model with nested random effects but, as recent discussion has indicated, this is not so straightforward. >As you can see different patients have one or two biopsies taken from >them. Since I realize it would be a mistake to include all those into the >target file because if I have more measurements of a certain patient that >would bias the ranking of the B-stat towards the patient having the most >biopsies in the end, right? Or? >Since the differentially expressed genes in the patient with more biopsies >will get smaller variance? > >My solution to the problem was just to create an artificial Mmatrix twice >as long as the original MA object. For the patients with two biopsies I >averaged over the technical replicates (dye-swaps) and put the values from >biopsy one and then the values from biopsy two in the matrix. From >patients with just a technical replicate I put the values from >hybridization 1A and then hybridization 1B into the matrix. > >The M-values of that matrix object would look something like: > > patient > 1 patient3 .... >Rows 1-30000 Hybridization 1A Average of hybridization 2A and >2B .... >Rows 30001-60000 Hybridization 1B Average of hybridization >3A and 3B .... > >After this I plan to use dupcor on the new matrix of M-values, as if I >would have a slide with replicate spots on it. > >So far so good or? Is this a good way of treating replicates on different >levels or has anyone else some better idea of how to do this. Comments >please..... This is actually very clever. You've got rid of one error strata by averaging, then use duplicateCorrelation to handle the other. I think your approach is actually a good one *but* you need to give double weight to cases where you have averaged over two technical replicates. Use the 'weights' component of your MAList object to do this. >And now, how to create a correct targets file since I have no common >reference. >I guess it would look something like this: > >SlideNumber Name FileName Cy3 Cy5 >1 pat1_p test1.gpr Before_p1 After_p1 >2 pat3_p test2.gpr Before_p2 After_p2 >3 pat4_p test3.gpr Before_p3 After_p3 >4 pat6_p test4.gpr Before_p4 After_p4 >5 pat7_p test5.gpr Before_p5 After_p5 >6 pat10_p test6.gpr Before_p6 After_p6 > >But when I want to make my contrast matrix I am lost since I do not have >anything to write as ref. >design <- modelMatrix(targets, ref="????????") If I have understood your approach, you don't need to do anything about the targets file or the design matrix. Just use design <- rep(1,6). You now have independent M-values estimating the same thing. Gordon >If I redo the matrix to > >SlideNumber Name FileName Cy3 Cy5 >1 pat1_p test1.gpr Before_p After_p >2 pat3_p test2.gpr Before_p After_p >3 pat4_p test3.gpr Before_p After_p >4 pat6_p test4.gpr Before_p After_p >5 pat7_p test5.gpr Before_p After_p >6 pat10_p test6.gpr Before_p After_p > >wouldnt that be the same as treating this as a common reference design >when it is not? And wouldnt that effect the variance of the experiment? >How do I do this in a correct way. >I looked at the Zebra fish example in the LIMMA user guide but isnt that >wrong as well. Because technical and biological replicates are treated the >same way in the targets file of the zebra fish. > >I realize that many of these questions should have been considered before >conducting the lab part but unfortunately they were not. So I will not be >surprised if someone sends me the same quote as I got yesterday from a friend: > >"To consult a statistician after an experiment is finished is often merely >to ask him to conduct a post mortem examination. He can perhaps say what >the experiment died of." >- R.A. Fisher, Presidential Address to the First Indian Statistical >Congress, 1938 > >Best regards > >/Johan Lindberg
ADD COMMENT

Login before adding your answer.

Traffic: 966 users visited in the last hour
Help About
FAQ
Access RSS
API
Stats

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.

Powered by the version 2.3.6